Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Adma Biologics' Other Working Capital Changes fell 12777.92% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$538000.0, marking a year-over-year decrease of 11212.26%. This contributed to the annual value of $2.7 million for FY2024, which is 102761.51% up from last year.
  • Per Adma Biologics' latest filing, its Other Working Capital Changes stood at -$1.1 million for Q3 2025, which was down 12777.92% from -$501000.0 recorded in Q2 2025.
  • Adma Biologics' Other Working Capital Changes' 5-year high stood at $4.0 million during Q3 2024, with a 5-year trough of -$1.6 million in Q1 2024.
  • Its 5-year average for Other Working Capital Changes is $313736.8, with a median of -$100745.0 in 2021.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first skyrocketed by 5670424.57% in 2021, then plummeted by 76784.14% in 2024.
  • Over the past 5 years, Adma Biologics' Other Working Capital Changes (Quarter) stood at -$1.5 million in 2021, then skyrocketed by 81.76% to -$277238.0 in 2022, then skyrocketed by 181.88% to $227000.0 in 2023, then crashed by 767.84% to -$1.5 million in 2024, then grew by 26.32% to -$1.1 million in 2025.
  • Its Other Working Capital Changes stands at -$1.1 million for Q3 2025, versus -$501000.0 for Q2 2025 and $2.6 million for Q1 2025.